Milan, Italy

Aldo Laguzzi

This inventor holds 1 USPTO granted patent. Top assignee: Instituto Farmacologico Lombardo-Iflo, S.a.s.. Active years: 1996.


% Patents Active = 100.0

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 7(Granted Patents)


Company Filing History:


Years Active: 1996

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Aldo Laguzzi: Innovator in Circadian Rhythm Treatments

Introduction

Aldo Laguzzi is a notable inventor based in Milan, Italy. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of circadian rhythm-related pathologies. His innovative approach has led to the development of novel compounds that exhibit superior activity in this area.

Latest Patents

Aldo Laguzzi holds a patent for "Compounds effective in the treatment of circadian rhythms and related." This patent describes novel compounds with specific chemical formulas that demonstrate effectiveness in treating conditions that interfere with circadian rhythms. The compounds are designed for transdermal administration, resulting in sustained peripheral blood levels, which enhances their therapeutic efficacy.

Career Highlights

Laguzzi is associated with Instituto Farmacologico Lombardo-Iflo, S.a.s., where he has been instrumental in advancing research and development in pharmaceutical compositions. His work focuses on creating innovative methods of drug administration that improve patient outcomes.

Collaborations

Throughout his career, Aldo Laguzzi has collaborated with esteemed colleagues such as Franco Fraschini and Bojidar Stankov. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise in the field of pharmacology.

Conclusion

Aldo Laguzzi's contributions to the treatment of circadian rhythm disorders highlight his innovative spirit and dedication to improving healthcare. His work continues to influence the pharmaceutical industry and offers hope for better management of related health issues.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…